| Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade |
54 |
| Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation |
13 |
| Demonstrating the value of the oncology pharmacist within the healthcare team |
12 |
| Pembrolizumab-induced myasthenia gravis: A fatal case report |
11 |
| Adherence to oral chemotherapy: Challenges and opportunities |
11 |
| Updates and novel treatments in urothelial carcinoma |
9 |
| Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen |
8 |
| Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events |
8 |
| Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors |
7 |
| Late-onset Stevens-Johnson syndrome due to nivolumab use for hepatocellular carcinoma |
7 |
| Stevens-Johnson syndrome manifesting late in the course of pembrolizumab therapy |
7 |
| Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature |
7 |
| Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor therapy |
7 |
| Evaluation of the prescribing patterns, adverse effects, and drug interactions of oral chemotherapy agents in an outpatient cancer center |
7 |
| Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment |
6 |
| Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report |
6 |
| The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy |
6 |
| Efficiency of degradation or desorption methods in antineoplastic drug decontamination: A critical review |
6 |
| Impact of pharmacist interventions on cost avoidance in an ambulatory cancer center |
6 |
| A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience |
6 |
| The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: A mini case series |
6 |
| BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia |
6 |
| Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents? |
6 |
| Integration of clinical pharmacists into an ambulatory, pediatric hematology/oncology/transplant clinic |
5 |
| Patient perspectives on the barriers associated with medication adherence to oral chemotherapy |
5 |
| Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience |
5 |
| Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors |
5 |
| Multicenter study of environmental contamination with cyclophosphamide, ifosfamide, and methotrexate in 48 Canadian hospitals |
5 |
| Nivolumab-induced aplastic anemia: A case report and literature review |
5 |
| Surface contamination with ten antineoplastic drugs in 83 Canadian centers |
5 |
| Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics |
5 |
| Impact of pharmacy collaborating services in an outpatient clinic on improving adverse drug reactions in outpatient cancer chemotherapy |
5 |
| A systematic review of the impact of outpatient clinical pharmacy services on medication-related outcomes in patients receiving anticancer therapies |
5 |
| A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice |
5 |
| A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity |
4 |
| Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study |
4 |
| Drug-drug interactions in patients receiving tyrosine kinase inhibitors |
4 |
| Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia |
4 |
| Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities |
4 |
| Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer |
4 |
| Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia |
4 |
| Application of the 2015 proposed NIOSH vapor containment performance protocol for closed system transfer devices used during pharmacy compounding and administration of hazardous drugs |
4 |
| Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignanciesA single institution experience and a review of literature |
4 |
| Potential role of rituximab in metastatic castrate-resistant prostate cancer |
4 |
| Safety and efficacy of a urine alkalinization protocol developed for high-dose methotrexate patients during intravenous bicarbonate shortage |
4 |
| Evaluation of the head and neck cancer patient population and the incidence of hospitalization at an academic medical center |
4 |
| User acceptance of an app-based adherence intervention: Perspectives from patients taking oral anticancer medications |
4 |
| Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient |
4 |
| Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation |
4 |
| Characterization of collaborative practice agreements held by hematopoietic stem cell transplant pharmacists |
4 |
